Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
Clin Transl Sci ; 17(5): e13796, 2024 May.
Article in English | MEDLINE | ID: mdl-38712716

ABSTRACT

Apomorphine, used to treat OFF episodes in patients with Parkinson's disease (PD), is typically administered via subcutaneous injections. Administration of an oromucosal solution could offer a non-invasive and user-friendly alternative. This two-part clinical study evaluated the safety, tolerability, pharmacokinetics (PK), and dose proportionality of a novel apomorphine hydrochloride oromucosal solution, as well as its relative bioavailability to subcutaneous apomorphine injection and apomorphine sublingual film. In part A of the study, 12 patients with PD received 2 mg oromucosal apomorphine (4% weight/volume) and 2 mg subcutaneous apomorphine in a randomized order, followed by 4 and 8 mg oromucosal apomorphine. In part B of the study, 13 patients with PD received 7 mg oromucosal apomorphine (7% weight/volume) and 30 mg sublingual apomorphine in a randomized order, followed by 14 mg oromucosal apomorphine. Washout between dose administrations in both study parts was at least 2 days. Safety, tolerability, and PK were assessed pre- and post-dose. Both study parts showed that oromucosal apomorphine was generally well-tolerated. Observed side effects were typical for apomorphine administration and included asymptomatic orthostatic hypotension, yawning, fatigue, and somnolence. Oromucosal apomorphine exposure increased with dose, although less than dose proportional. The mean (SD) maximum exposure reached with 14 mg oromucosal apomorphine was 753.0 (298.6) ng*min/mL (area under the plasma concentration-time curve from zero to infinity) and 8.0 (3.3) ng/mL (maximum plasma concentration). This was comparable to exposure reached after 2 mg subcutaneous apomorphine and approximately half of the exposure observed with 30 mg sublingual apomorphine. In summary, clinically relevant plasma concentrations could be reached in PD patients without tolerability issues.


Subject(s)
Apomorphine , Parkinson Disease , Humans , Apomorphine/administration & dosage , Apomorphine/pharmacokinetics , Apomorphine/adverse effects , Parkinson Disease/drug therapy , Male , Middle Aged , Female , Aged , Administration, Sublingual , Injections, Subcutaneous , Dose-Response Relationship, Drug , Administration, Oral , Biological Availability , Antiparkinson Agents/administration & dosage , Antiparkinson Agents/pharmacokinetics , Antiparkinson Agents/adverse effects , Cross-Over Studies
2.
Ned Tijdschr Geneeskd ; 1652021 11 25.
Article in Dutch | MEDLINE | ID: mdl-35129888

ABSTRACT

BACKGROUND: An epileptic seizure is a common neurological presentation in the Emergency Department (ED). Electrolyte disturbances are an important cause of neurological symptoms like seizures and hypomagnesemia is one of them. PPI's can cause hypomagnesemia and are readily prescribed. Therefore patients taking PPI's are at risk of developing neurological symptoms due to hypomagnesemia. CASE: A 82-year old woman was seen in ED with a history of nausea, vomiting and vertigo. A vertical nystagmus was observed with attacks of mydriasis followed by a phase of encephalopathy and restlessness. These were recognized as epilepsy. Hypokaliemia, hypocalcemia and a deep hypomagnesemia were present. The PPI accounted for hypomagnesemia. After 2 days of intravenous magnesium suppletion all symptoms disappeared. CONCLUSION: PPI's can cause hypomagnesemia and magnesium levels should be obtained in patients presenting with encephalopathy or atypical neurological symptoms.


Subject(s)
Hypocalcemia , Hypokalemia , Magnesium Deficiency , Aged, 80 and over , Female , Humans , Hypocalcemia/chemically induced , Hypokalemia/chemically induced , Magnesium , Magnesium Deficiency/chemically induced , Magnesium Deficiency/complications , Magnesium Deficiency/diagnosis , Proton Pump Inhibitors/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...